VNDA catalysts and FDA events, page 2.
Updated Snapshot 20261116T222116ZBuilt
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on VNDA PDUFA dates and upcoming catalysts. This page continues the list.
Past catalysts and FDA decisions (continued)
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Dec 2024Month disclosed | HETLIOZ® (tasimelteon) | VNDA | FDA approval | — | Approved | SEC Form 10-Q |
| Dec 2024Month disclosed | generic | VNDA | FDA approval | — | Approved | SEC Form 10-K |
| September 18, 2024 | NEREUSTM (tradipitant) | VNDA | PDUFA date | symptoms of gastroparesis to a final decision prior | CRL issued | SEC Form 10-Q |
| September 18, 2024 | NEREUSTM (tradipitant) | VNDA | Complete Response Letter | — | CRL issued | SEC Form 10-K |
| March 4, 2024 | — | VNDA | Complete Response Letter | — | CRL issued | SEC Form 10-K |
| March 4, 2024 | HETLIOZ® (tasimelteon) | VNDA | PDUFA date | — | Scheduled | SEC Form 10-K |
| Jan 2024Month disclosed | VTR-297 | VNDA | FDA approval | onychomycosis, a fungal infection of the nail | Approved | SEC Form 10-K |
| Jan 2024Month disclosed | VCA-894A | VNDA | FDA approval | patient with CMT2S | Approved | SEC Form 10-K |
| Dec 2023Month disclosed | NEREUSTM (tradipitant) | VNDA | NDA/BLA accepted | — | Completed | SEC Form 10-K |
| Dec 2023Month disclosed | NEREUSTM (tradipitant) | VNDA | FDA approval | vomiting induced | Approved | SEC Form 10-K |
| Jul 2023Month disclosed | HETLIOZ® (tasimelteon) | VNDA | NDA/BLA accepted | — | Completed | SEC Form 10-K |
| Dec 2022Month disclosed | HETLIOZ® (tasimelteon) | VNDA | FDA approval | — | Approved | SEC Form 10-Q |
| Dec 2022Month disclosed | generic | VNDA | FDA approval | — | Approved | SEC Form 10-K |
| Sep 2022Month disclosed | HETLIOZ® (tasimelteon) | VNDA | NDA/BLA submission | jet lag disorder | Completed | SEC Form 10-Q |
Every catalyst is quoted from VNDA’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.